Preclinical assessment of ulixertinib, a novel ERK1/2 inhibitor

Vinod A Balakrishna¹, Anitha Police¹, Rakesh A Hiremath², Anusha Raj², Suresh P Sulochana¹, Devaraj V Chandrasekhar¹, Mohd Zainuddin¹, Ravi Kanth Bhamidipati¹ and Ramesh Mullangi¹*

¹ Drug Metabolism and Pharmacokinetics, Jubilant Biosys, Industrial Suburb, Yeshwanthpur, Bangalore-560 022, India
² J.S.S College of Pharmacy, Mysore, India

*Corresponding Author: E-mail: mullangi.ramesh@jubilantinnovation.com; Tel.: 9611333488

Received: September 08, 2017; Revised: October 03, 2017; Published: December 24, 2017

Abstract

Ulixertinib (BVD-523) is a novel and selective reversible inhibitor of ERK1/ERK2. In xenograft studies it inhibited tumor growth in BRAF-mutant melanoma and colorectal xenografts as well as KRAS-mutant colorectal and pancreatic models. Ulixertinib is currently in Phase I clinical development for the treatment of advance solid tumors. The objective of the study is to assess the metabolic stability (in various preclinical and human liver microsomes/hepatocytes), permeability, protein binding, CYP inhibition, CYP induction and CYP phenotyping of ulixertinib. We have also studied the oral and intravenous pharmacokinetics of ulixertinib in mice, rats and dogs. Ulixertinib was found to be moderately to highly stable in various liver microsomes/hepatocytes tested. It is a medium permeable (2.67 x 10⁻⁶ cm /sec) drug and a substrate for efflux (efflux ratio: 3.02) in Caco-2 model. Ulixertinib was highly bound to plasma proteins. CYPs involved in its limited metabolism and it is CYP inhibition IC₅₀ ranged between 10-20 µM. Post oral administration ulixertinib exhibited early Tₘₐₓ (0.50-0.75 h) in mice and rats indicating absorption was rapid, however in dogs Tₘₐₓ attained at 2 h. The half-life (t½) of ulixertinib by intravenous and oral routes ranged between 1.0-2.5 h across the species. Clearance and volume of distribution by intravenous route for ulixertinib were found to be 6.24 mL/min/kg and 0.56 L/kg; 1.67 mL/min/kg and 0.36 L/kg and 15.5 mL/min/kg and 1.61 L/kg in mice, rats and dogs, respectively. Absolute oral bioavailability in mice and rats was > 92 %, however in dogs it was 34 %.

Keywords

Ulixertinib; ERK inhibitor; In vitro studies; Pharmacokinetics; Mice; Rats; Dogs

Introduction

The extracellular-signal-regulated kinases, ERK1 and ERK2 (ERK1/2), play a critical role in the RAS/RAF/MEK signaling pathway, that controls several fundamental cellular processes, driving proliferation, differentiation and cell survival [1]. RAS/RAF/MEK signaling pathway is frequently activated by mutations in upstream targets such as BRAF, RAS and receptor tyrosine kinases [2]. Most of the resistance mechanisms to BRAF and MEK inhibitors ultimately lead to increase in phosphorylation of ERK1/2 suggesting the importance of this node in the RAS/RAF/MEK pathway even in the resistance setting [3]. RAS activating mutations have been reported in about 90 % of pancreatic carcinomas, followed by colon carcinomas (50 %), lung cancers and myeloid leukemia cases (30 % each) [4]. Therefore, inhibition of
ERK1/2 offers a promising strategy to address both innate and acquired resistance to BRAF and MEK inhibitors in various solid tumors. Ulixertinib (BVD-523, VRT52271; Figure 1) is a first-in-class novel small molecule, which potently and selectively inhibits ERK1/2 kinases in a reversible, ATP-competitive fashion. Inhibition of ERK1/2 leads to proliferation inhibition (by decreasing the expression of VEGFA and VEGFR2 at mRNA and protein level), cell cycle arrest and apoptosis in lymphoma cell lines [5]. Ulixertinib inhibits tumor growth in vivo in BRAF-mutant melanoma and colorectal xenografts as well as in KRAS-mutant colorectal and pancreatic models [6]. In clinical studies, ulixertinib was well tolerated by patients with advanced solid tumors. In an oral Phase-I dose escalation study (having 9 doses) with an end point to determine the dose limited toxicities (DLT), maximum tolerated dose (MTD) along with pharmacokinetic profile and preliminary efficacy assessment it was administered in a dose range of 10-900 mg in a b.i.d regimen. Ulixertinib showed linear pharmacokinetics up to 600 mg (b.i.d), this was found to be MTD [7].

To date there is no publication on preclinical pharmacokinetics of ERK1/2 inhibitors, hence we felt that preliminary data on various in vitro ADME studies and in vivo pharmacokinetics in mice, rats and dogs of ulixertinib will help researchers in this field to provide the differentiating features in this class. This paper describes various in vitro experiments done to (a) assess the metabolic stability of ulixertinib in various preclinical species and human liver microsomes and hepatocytes (b) determine the permeability in Caco-2 cells (c) determine the unbound fraction in preclinical species and human plasma (d) CYP inhibition (e) CYP induction and (f) CYP phenotyping of ulixertinib. Moreover, a series of in vivo experiments in Balb/C mice, Sprague Dawley rats and Beagle dogs were performed to characterize and understand pharmacokinetic parameters and absolute oral bioavailability of ulixertinib across the species.

Materials and methods

Materials

Ulixertinib (purity >99 %) was purchased from MedKoo Biosciences, Inc., NC, USA. HPLC grade acetonitrile, formic acid and methanol were purchased from Rankem, Ranbaxy Fine Chemicals Limited, New Delhi, India. Preclinical species and human liver microsomes and hepatocytes were purchased from Life Technologies (Gibco®), Inchinnan, UK. Substrates and inhibitors of CYP isoforms like midazolam, quinidine, diclofenac, bufuralol, omeprazole, verapamil, rifampicin, warfarin, tolbutamide, phenacetin, ketoconazole, sulfaphenazole, nootkatone, furafylline and digoxin were purchased from Sigma-Aldrich Chemie GmbH, Steinheim, Germany. All other chemicals/reagents were of research grade and used without further purification.
**In vitro studies**

**Metabolic stability in liver microsomes**

Metabolic stability is defined as the percentage of parent compound lost over time in the presence of a metabolically active test system. The incubation mixtures consisted of liver microsomes (0.5 mg microsomal protein/mL), ulixertinib (1 μM) or positive control (verapamil, 1 μM). The reactions were initiated by adding 20 μL of 10 mM NADPH [8]. Reactions without NADPH (0 and 30 min) were also incubated to rule out non-NADPH metabolism or chemical instability in the incubation buffer [8]. All reactions were terminated using 200 μL of ice-cold acetonitrile containing internal standard (200 ng/mL of phenacetin) at 0, 5, 15 and 30 min. The vials were centrifuged at 3000 rpm (Eppendorf 5424R, Germany) for 15 min. The supernatants thus obtained were analyzed on LC-MS/MS to monitor the disappearance of ulixertinib.

**Metabolic stability in hepatocytes**

After checking the viability of cryopreserved hepatocytes, they were distributed 1 million viable cells per mL. An aliquot of 100 μL of thawed hepatocytes cell suspension was aliquotted into different vials labeled as 0, 30, 60, 120 and 180 min (mouse, rat, dog or human hepatocytes) and ulixertinib (3 μM). Imipramine or naloxone (3 μM) was used as a positive control [9]. The vials were pre-incubated in a 37 °C water bath for 5 min. All reactions were terminated using 200 μL of ice-cold acetonitrile containing internal standard (200 ng/mL of phenacetin) at specified time points. The vials (having reaction mixture terminated contents) were centrifuged at 3000 rpm (Eppendorf 5424R, Germany) for 15 min. The supernatants thus obtained were analyzed on LC-MS/MS to monitor the disappearance of ulixertinib. Clearance rate and half-life were calculated using the obtained data.

**Caco-2 permeability**

Caco-2 human intestinal epithelial cells were plated in 24-Transwell® dual chamber plates (Millipore, Billerica, MA, USA) (cell density of 80,000 cells/cm² on day-1). The permeability studies were conducted with the monolayers cultured for 21 to 22 days. The integrity of each Caco-2 cell monolayer was certified by trans epithelial electrical resistance (TEER) test (pre-experiment) and by determining the permeability of reference compound i.e., Lucifer yellow. Caco-2 cell monolayers with TEER values greater than 500 Ω cm² were considered for experimentation. Digoxin (5 μM) was used as a positive control for P-gp substrate [10]. The concentration of ulixertinib used in the assay was 10 μM. HBSS Buffer was used as the medium for the transport assay and the final concentration of DMSO in spiking solution was 0.05 %. The bi-directional permeability study was initiated by adding an appropriate volume of HBSS buffer containing ulixertinib to respective apical and basolateral chambers (n=2) [11]. An aliquot of sample (100 μL) was taken from both chambers at 0 and 60 min of the incubation period and to this equal volume of acetonitrile with internal standard (200 ng/mL of phenacetin) was added, mixed gently and centrifuged at 4000 rpm (Eppendorf 5424R, Germany) for 10 min. An aliquot of 100 μL was subsequently transferred to the auto-sampler and injected for analysis on LC-MS/MS.

**Plasma protein binding**

To evaluate the ability of ulixertinib to bind the plasma proteins, the most common approach of plasma protein binding using equilibrium dialysis was used [12]. Ulixertinib was tested at a final concentration of 3 μM in mouse, rat and dog plasma. An aliquot of 150 μL plasma containing ulixertinib was added in first half (plasma side) of the well of 96-well micro-equilibrium dialysis device. An aliquot of 150 μL of 100 mM...
sodium phosphate buffer pH 7.4 was added in the second half (buffer side) of the well of 96-well HT equilibrium dialysis device. The plate containing plasma and buffer was equilibrated at 37 ± 1 °C for 4.5 h, with constant shaking at 120 rpm on an orbital shaker. Samples were collected from respective halves after the completion of incubation time. The proteins were precipitated using organic solvents. The samples were subjected to centrifugation and the supernatants were analyzed on LC-MS/MS.

CYP inhibition

CYP inhibition potential of ulixertinib was assessed in human liver microsomes [Life Technologies (Gibco®), Inchinnan, UK] against CYP3A4, 2D6, 1A2, 2C9 and 2C19 in the following sequential steps. Standard reaction mixture (final volume 300 μL) contained 66.7 M potassium phosphate buffer (pH 7.4), protein [0.1 (for CYP3A4), 0.25 (for CYP2D6), 0.5 mg/mL (for CYP1A2, 2C9 and 2C19)] and ulixertinib (at 2.0, 10 and 20 μM, added as 0.9 μL DMSO solution with a final DMSO concentration of 0.1 %). The mixtures were pre-incubated at 37 ± 1 °C for 5 min. The reaction (in duplicate) was initiated by addition of 30 μL of NADPH (10 mM) [13]. Reaction was terminated at 10 min by adding 300 μL of ice cold acetonitrile with internal standard. The activity of liver microsomes was confirmed with positive controls i.e., monitoring the hydroxylation of midazolam, bufuralol, diclofenac and omeprazole for CYP3A4, 2D6, 2C9 and 2C19, respectively and deethylation of phenacetin for CYP1A2 (data not shown). The reaction mixtures (obtained from the above studies) were extracted, processed, analyzed on LC-MS/MS.

rhCYP metabolism

To evaluate the metabolism of ulixertinib, the most common approach of reaction phenotyping by using cDNA expressed enzyme system was used. Ulixertinib was incubated with a panel of individually-expressed recombinant human CYP enzymes (CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6 and 3A4, purchased from Life Technologies (Gibco®), Inchinnan, UK expressed in baculovirus-infected insect cell membranes. The incubation mixture contained ulixertinib at a final concentration of 0.1 μM, expressed CYP enzyme (50 pmol/mL), phosphate buffer (66.7 mM, pH 7.4) in a total volume of 1 mL. The reaction was initiated by the addition of 20 μL of NADPH after pre-incubation of the aliquots (180 μL) marked 0, 5, 15, 30 and 60 min followed by incubation at 37 ± 1 °C. The reaction was terminated by the addition of equal volumes of ice cold acetonitrile with internal standard (200 ng/mL of phenacetin). The samples were centrifuged at 3000 rpm (Eppendorf 5424R, Germany) at 4 °C for 20 min to precipitate proteins. Supernatants were then transferred to clean vials and stored at -20 °C until analysis. Incubations without NADPH were used as negative controls. Control incubations using probe substrates for individual recombinant humans CYPs were included to check for appropriate incubation conditions and as positive control for activity [15]. The samples were analyzed on LC-MS/MS. Disappearance of ulixertinib was compared to that of control treatment (no CYP enzymes present) in order to assess the contribution of a given CYP in ulixertinib metabolism.

In vivo studies

Formulations

For oral administration a suspension formulation was prepared using Tween-80 and 0.5 % methyl cellulose. Weighed amount of ulixertinib was taken into a mortar and grinded into a fine powder with the help of a pestle. To this Tween-80 was added drop wise to wet the entire powder. Then slowly 0.5 % methyl cellulose was added with constant stirring to get a uniform suspension. The final strength of the suspension formulation was 10 mg/mL and it was administered to animal species at 10 mL/kg body weight. For intravenous (i.v.) administration a solution formulation was used (prepared using 10 % DMSO, 10 %
Solutol: absolute ethyl alcohol (1:1, v/v) and 80 % normal saline. The volume of administration for intravenous was 10 mL/kg for mice and 2 mL/kg for rats and dogs.

Animal experiments details

Institutional Animal Ethical Committee (IAEC) of Jubilant Biosys (IAEC/JDC/2017/121) nominated by CPCSEA (Committee for the Purpose of Control and Supervision of Experiments on Animals) approved the rodents pharmacokinetic experiments. Male Sprague Dawley rats (~7-8 weeks old) and BalbC mice (~6-10 weeks old) were purchased from Vivo Biotech, Hyderabad, India. Animals were quarantined in Jubilant Biosys Animal House for a period of 7 days with a 12:12 h light:dark cycles, had free access to rodent food (Altromin Spezialfutter GmbH & Co. KG., Im Seelenkamp 20, D-32791, Lage, Germany) and water ad libitum. For all the experimental work animals were kept for fasting (4 h for BalbC mice and 12 h for Sprague Dawley rats) and during this time they were allowed to take water ad libitum. Food was provided 2 h post-dose and water was allowed ad libitum.

IAEC of Palamur Biosciences, Telangana, India (1312/PO/RcBiBt/S/L/09/CPCSEA) approved studies conducted in dogs. Male Beagle dogs (~1.0-1.5 year old) were housed in Palamur Biosciences Private Limited animal house facility in a temperature (18-28 °C) and humidity (30-70 %) controlled room and fed with Pedigree standard pellet food and water ad libitum for one week before using for experimental purpose. For all the experimental work animals were kept for 12 h overnight fasting and during this time they were allowed to take water ad libitum. Food was provided 4 h post-dose and water was allowed ad libitum.

Pharmacokinetic studies

Oral bioavailability of ulixertinib was evaluated in male Balb/C mice, Sprague Dawley rats and Beagle dogs. Fasted mice (~4 h) and rats (overnight ~12 h) were divided into two groups (mice: 12/group; rats: 4/group), however in cases of dogs (n=2; fasted for ~12 h overnight) same dogs were dose after one week wash-out period (cross over design). In each species Group-1 animals received ulixertinib through intravenous route at a dose of 1 mg/kg; whereas Group 2 received ulixertinib through oral gavage at 10 mg/kg dose. Serial blood samples [100 µL in case of mice (sparse sampling; n=3 at each time point) and rats; 500 µL in dogs] were collected from retro-orbital plexus at 0.12, 0.25, 0.5, 1, 2, 4, 8, and 24 h (intravenous administration) or at 0.25, 0.5, 1, 2, 4, 8, 10 and 24 h (oral administration) after drug administration. Blood samples were collected in tubes containing K₂EDTA as the anticoagulant and centrifuged for 5 min at 14000 rpm in a refrigerated centrifuge (Biofuge, Heraeus, Germany) maintained at 4 °C for plasma separation and stored frozen at -80 ± 10 °C until analysis.

Sample processing

In vitro studies samples analysis

A Shimadzu (Shimadzu, Kyoto, Japan) SIL series LC system equipped with a degasser (DGU-20A3), isopump (LC-20 AD) and column oven (CTO-10AS) along with an auto-sampler (SIL-HTc) was used to inject 10 µL aliquots of the processed samples on a Atlantis C₁₈ column (50 x 4.6 mm, 3 µm; Waters, Ireland, UK), which was maintained at 40 °C. The mobile phase system consisted of reservoir A (acetonitrile) and reservoir B (0.2 % formic acid in water) were run as per gradient program (0-0.1 min: 10 % A and 90 % B; 0.1-2.8 min: 100 % A; 2.9-4.0 min 10 % A and 90 % B). A flow rate of 0.8 mL/min with a 50 % splitter was used throughout the analytical run. Quantitation was achieved by MS/MS detection in positive ion mode for ulixertinib using an API-4000 Q Trap mass spectrometer (MDS Sciex, Toronto, Canada) equipped with a
Turboionspray™ interface at 450 °C temperature and 5500 V ion spray voltage. The source parameters viz., curtain gas, GS1, GS2 and CAD were set at 30, 35, 40 and 6 psi. The compound parameters viz., declustering potential (DP), entrance potential (EP), collision energy (CE) and collision cell exit potential (CXP) were 81, 10, 49 and 15 V for ulixertinib and 80, 10, 29 and 14 V for the IS. Detection of the ions was performed in the multiple reaction monitoring (MRM) mode, monitoring the transition of the m/z 433 precursor ion to the m/z 262 product ion for ulixertinib and m/z 180 precursor ion to the m/z 110 product ion for the IS. Quadrupole Q1 and Q3 were set on unit resolution. The dwell time was 150 msec.

**Plasma samples processing and analysis**

An aliquot of 50 µL plasma sample was precipitated with 200 µL of acetonitrile:methanol (1:1, v/v) enriched with internal standard (200 ng/mL of phenacetin) and centrifuged at 14,000 rpm for 5 min (Eppendorf 5424R, Germany) at 5 °C. Clear supernatant (125 µL) was transferred into vials and 5 µL of supernatant was injected onto LC-MS/MS system for analysis using a validated method [16]. The linearity range was 1.05-2096 ng/mL. In-study quality control (QC) samples, supplemented with concentrations of 3.14, 1048 and 1747 ng/mL of ulixertinib, were analysed with the unknowns. Plasma samples showing high concentration above the high calibration standard were diluted with appropriate animal species blank plasma to bring the concentration within linearity range.

For plasma samples analysis the criteria for acceptance of the analytical runs encompassed the following: (i) 67 % of the QC samples accuracy must be within 85-115 % of the nominal concentration (ii) not less than 50 % at each QC concentration level must meet the acceptance criteria. Following completion of the analysis both the linearity and quality control samples values were found to be within the accepted variable limits.

**Pharmacokinetic Analysis**

Pharmacokinetic parameters were calculated by a non-compartmental method using Phoenix WinNonlin 7.0 software (Pharsight, Mountain View, CA, USA). Absolute oral bioavailability (F) was calculated using the relationship, 
\[ F = \frac{\text{Dose (i.v.) x AUC}_{(0-\infty)\text{oral}}}{\text{Dose (oral)} x \text{AUC}_{(0-\infty)\text{i.v.}}} \times 100. \]

**Results**

**In vitro studies**

**Metabolic stability in liver microsomes**

Metabolic stability of ulixertinib in different species of liver microsomes is presented in Table 1. Ulixertinib was found to be moderately stable in mice and dog liver microsomes and highly stable rat and human liver microsomes.

**Metabolic stability in hepatocytes**

Hepatocyte stability of ulixertinib in different species is presented in Table 2. Ulixertinib was found to be highly stable in rat and human hepatocytes but moderately stable in mice and dog hepatocytes. The in vivo intrinsic clearance (Clint) was relatively low to moderate in rat and human hepatocytes but high in mice and dog hepatocytes.

**Caco-2 permeability**

Table 3 shows the rate of transport (P_app) of ulixertinib and digoxin from A → B and B → A along with efflux ratio values. The findings suggested that ulixertinib is a medium permeable compound and may be a
substrate of an active efflux transporter.

### Table 1. Metabolic stability data of ulixertinib at 1 µM in liver microsomes of various preclinical species

<table>
<thead>
<tr>
<th>Species</th>
<th>Percent metabolized</th>
<th>t_½ (min)</th>
<th>mCl_{int} (µL/min/mg)</th>
<th>Cl_{int} (mL/min/kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mice</td>
<td>44.5</td>
<td>36</td>
<td>19.3</td>
<td>27.7</td>
</tr>
<tr>
<td>Rat</td>
<td>16.4</td>
<td>122</td>
<td>5.7</td>
<td>7.6</td>
</tr>
<tr>
<td>Dog</td>
<td>35.5</td>
<td>52</td>
<td>13.3</td>
<td>9.1</td>
</tr>
<tr>
<td>Human</td>
<td>12.8</td>
<td>142</td>
<td>9.8</td>
<td>5.4</td>
</tr>
</tbody>
</table>

### Table 2. Hepatocyte stability data of ulixertinib at 3 µM in liver hepatocytes of various preclinical species

<table>
<thead>
<tr>
<th>Species</th>
<th>Percent metabolized</th>
<th>t_½ (min)</th>
<th>hCl_{int} (mL/min/10^6 cells)</th>
<th>Cl_{int scaled} (mL/min/kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mice</td>
<td>79</td>
<td>78</td>
<td>8.9</td>
<td>41.3</td>
</tr>
<tr>
<td>Rat</td>
<td>27</td>
<td>410</td>
<td>1.7</td>
<td>7.1</td>
</tr>
<tr>
<td>Dog</td>
<td>76</td>
<td>73</td>
<td>9.1</td>
<td>16.4</td>
</tr>
<tr>
<td>Human</td>
<td>37</td>
<td>306</td>
<td>2.3</td>
<td>5.0</td>
</tr>
</tbody>
</table>

### Table 3. Permeability data of ulixertinib in Caco-2 cell monolayers

<table>
<thead>
<tr>
<th>Compound</th>
<th>Concentration (µM)</th>
<th>% Recovery</th>
<th>Permeability (x 10^6 cm/sec)</th>
<th>Efflux ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>B → A</td>
<td>A → B</td>
<td>B → A</td>
<td>A → B</td>
</tr>
<tr>
<td>Ulixertinib</td>
<td>10</td>
<td>79</td>
<td>65</td>
<td>8.09</td>
</tr>
<tr>
<td>Digoxin</td>
<td>5.0</td>
<td>98</td>
<td>75</td>
<td>10.5</td>
</tr>
</tbody>
</table>

### Plasma protein binding

Ulixertinib had a very high binding in rat plasma followed by mouse and dog plasma with fraction unbound of 0.001, 0.003 and 0.050, respectively. The stability and recovery of ulixertinib in plasma was good across the species tested.

### CYP inhibition

The predicted IC_{50} values of ulixertinib were determined for CYP-specific hydroxylation of midazolam, bufuralol, diclofenac and omeprazole for CYP 3A4, 2D6, 2C9 and 2C19, respectively and deethylation of CYP1A2. Ulixertinib did not show notable inhibition against these enzymes and the predicted IC_{50} values of ulixertinib were found to be ~10 and 20 µM for CYP 3A4 and 2D6, respectively indicating it is a weak inhibitor against these two CYPs. Furthermore, its inhibitory effect was much weaker against CYP1A2, 2C9 and 2C19 as its IC_{50} was > 20 µM. Thus, when compared with known inhibitors, ulixertinib shows less significant inhibition of CYP enzyme activity in vitro (Table 4).

### CYP induction
Ulixertinib was tested at two different concentrations (1 and 10 µM). The readings suggested no or very less percent activation compared against rifampicin, a known CYP3A4 inducer.

<table>
<thead>
<tr>
<th>Inhibitor</th>
<th>CYP3A4</th>
<th>CYP2D6</th>
<th>CYP2C9</th>
<th>CYP2C19</th>
<th>CYP1A2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ulixertinib</td>
<td>~10</td>
<td>~20</td>
<td>&gt;20</td>
<td>&gt;20</td>
<td>&gt;20</td>
</tr>
<tr>
<td>Ketoconazole</td>
<td>0.08</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
</tr>
<tr>
<td>Quinidine</td>
<td>NT</td>
<td>0.12</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
</tr>
<tr>
<td>Sulphaphenazole</td>
<td>NT</td>
<td>NT</td>
<td>0.72</td>
<td>NT</td>
<td>NT</td>
</tr>
<tr>
<td>Nootkatone</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>1.02</td>
<td>NT</td>
</tr>
<tr>
<td>Furafylline</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>0.58</td>
</tr>
</tbody>
</table>

rhCYP metabolism

Data following incubations with different CYP isozymes (CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6 and 3A4) considered in the panel suggested very minimal contribution of CYP1A2, 2C9, 2C19, 2D6 and 3A4 towards the metabolism of ulixertinib involving oxidation and dealkylation. This data is corroborating with the work reported by Germann et al [6].

Pharmacokinetic studies

The profiles of plasma concentration for ulixertinib following single oral and intravenous administration to mice, rats and dogs are shown in Figure 2A and 2B, respectively. The estimates of pharmacokinetic parameters in these species are summarized in Table 5.

**Figure 2.** Plasma concentration-time profiles of ulixertinib after (A) oral (10 mg/kg) and (B) intravenous (1 mg/kg) administration to male Balb/C mice (mean ± S.D, n = 12), Sprague Dawley rats (mean ± S.D, n = 4) and Beagle dogs (mean, n = 2).
In the mice, plasma concentrations of ulixertinib decreased mono-exponentially manner after 1 mg/kg *intravenous* administration. The clearance was 6.24 mL/min/kg [7 % hepatic blood flow (HBF)]. The *in vivo* clearance was bit over predicted by the *in vitro* microsomes (~4-fold) and hepatocytes (~6-fold) scaled clearance. Ulixertinib had a high volume of distribution of 0.56 L/kg in mice, which is 38 times higher than that of total body water (TBW) of 0.015 L/kg [17]. The terminal $t_{1/2}$ was found to be 1.04 h. Post oral administration maximum plasma concentrations ($C_{\text{max}}$: 7768 ng/mL) attained at 0.5 h indicating rapid absorption from gastrointestinal tract. The terminal $t_{1/2}$ (2.06 h) determined after oral administration was longer than that after *intravenous* administration (1.04 h), which may indicate multiple sites absorption. The AUC$_{0-\infty}$ attained post oral dose was 24460 ng·h/mL. The oral bioavailability in mice at 10 mg/kg was 92 % (Table 5).

**Table 5.** Pharmacokinetic parameters of ulixertinib after *intravenous* and oral administration to mice, rats and dogs at 1 and 10 mg/kg, respectively

<table>
<thead>
<tr>
<th>Strain</th>
<th>Route of adm.</th>
<th>Dose (mg/kg)</th>
<th>AUC$_{0-\infty}$ (ng h/mL)</th>
<th>$C_{\text{max}}$/C$_0$ (ng/mL)</th>
<th>$T_{\text{max}}$ (h)</th>
<th>$t_{1/2}$ (h)</th>
<th>Cl (mL/min/kg)</th>
<th>Vd (L/kg)</th>
<th>F (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>BalbC mice</td>
<td>Intravenous</td>
<td>1.0</td>
<td>2672</td>
<td>1918</td>
<td>---</td>
<td>1.04</td>
<td>6.24</td>
<td>0.56</td>
<td>---</td>
</tr>
<tr>
<td></td>
<td>Oral</td>
<td>10</td>
<td>24460</td>
<td>7768</td>
<td>0.50</td>
<td>2.06</td>
<td>---</td>
<td>---</td>
<td>91.6</td>
</tr>
<tr>
<td>Sprague Dawley rats</td>
<td>Intravenous</td>
<td>1.0</td>
<td>10179 ± 1528</td>
<td>6644 ± 1812</td>
<td>---</td>
<td>2.52 ± 0.07</td>
<td>1.67 ± 0.25</td>
<td>0.36 ± 0.06</td>
<td>---</td>
</tr>
<tr>
<td></td>
<td>Oral</td>
<td>10</td>
<td>98421 ± 14005</td>
<td>15026 ± 2098</td>
<td>0.75 ± 0.29</td>
<td>2.02 ± 0.17</td>
<td>---</td>
<td>---</td>
<td>97.7</td>
</tr>
<tr>
<td>Beagle dogs</td>
<td>Intravenous</td>
<td>1.0</td>
<td>1091</td>
<td>1033</td>
<td>---</td>
<td>1.21</td>
<td>15.5</td>
<td>1.61</td>
<td>---</td>
</tr>
<tr>
<td></td>
<td>Oral</td>
<td>10</td>
<td>3687</td>
<td>1442</td>
<td>2.00</td>
<td>1.29</td>
<td>---</td>
<td>---</td>
<td>33.8</td>
</tr>
</tbody>
</table>

In the rats, plasma concentrations of ulixertinib decreased mono-exponentially manner after 1 mg/kg *intravenous* administration. The clearance was found to be 1.67 mL/min/kg (3 % of HBF), which is in good agreement with *in vitro* (microsomes and hepatocytes) scaled clearance. The volume of distribution (0.36 L/kg) of ulixertinib in rat is approximated to TBW. The terminal $t_{1/2}$ was found to be 2.52 h. In rats also post oral administration early $T_{\text{max}}$ of 0.75 h suggesting that ulixertinib has a rapid absorption from gastrointestinal tract. The AUC$_{0-\infty}$ and $C_{\text{max}}$ attained post oral dose was 98421 ng·h/mL and 15026 ng/mL, respectively. The terminal $t_{1/2}$ determined after oral administration is 2.02 h, which is comparable to *intravenous* route half-life. The oral bioavailability in rat at 10 mg/kg was 98 % (Table 5).

In the dogs also plasma concentrations of ulixertinib decreased mono-exponentially manner after 1 mg/kg *intravenous* administration. The clearance was 15.5 mL/min/kg (~50 % HBF). The *in vivo* clearance was in good agreement with *in vitro* (microsomes and hepatocytes) predicted scaled clearance. The apparent volume of distribution 1.61 L/kg of ulixertinib in dogs is approximated to TBW. The terminal $t_{1/2}$ was found to be 1.21 h. In dogs post oral administration, maximum plasma concentrations (1442 ng/mL) of ulixertinib observed at 2.00 h, indicating it is a delayed $T_{\text{max}}$ (when compared with $T_{\text{max}}$ value of rodents). The AUC$_{0-\infty}$ was 3687 ng·h/mL. The terminal $t_{1/2}$ determined after oral administration was 1.29 h. The oral bioavailability in dogs at 10 mg/kg was 34 % (Table 5).
Discussion

RAS/RAF/MEK signaling pathway is frequently activated in many cancers [2] and clinical efficacy of BRAF and MEK inhibitors confirms targeting RAS/RAF/MEK pathway has therapeutic potential and great promise [18]. Most of the resistance mechanisms to BRAF and MEK inhibitors ultimately lead to increase in phosphorylation of ERK1/2 [3]. Therefore, inhibition of ERK1/2 offers a promising strategy to address both innate and acquired resistance to BRAF and MEK inhibitors in various solid tumors. Ulixertinib is a novel compound, which selectively and potently inhibits ERK1/2 kinases in a reversible, ATP-competitive fashion. As a single-agent it inhibits tumor growth in vivo in BRAF-mutant melanoma and colorectal xenografts as well as in KRAS-mutant colorectal and pancreatic models [6]. In Phase-1 clinical studies, ulixertinib was well tolerated by patients with advanced solid tumors. Ulixertinib showed linear pharmacokinetics up to 600 mg (b.i.d), this was found to be MTD [7]. To the best of our knowledge there is no preclinical pharmacokinetic data reported for ERK1/2 inhibitors in the literature. Preclinical pharmacokinetics of a novel target class drug has great influence on the development and investigation of potential candidates for the further drug design, which necessitates a thorough exploration and understanding of pharmacokinetic disposition. This is important since in vivo pharmacokinetic behavior and pharmacokinetic-pharmacodynamic correlation act as surrogates for clinical effectiveness of potential drug candidates. In this paper we report the metabolic stability, permeability, protein binding, CYP inhibition, CYP induction, CYP phenotyping and pharmacokinetics in mice, rats and dogs for ulixertinib.

The metabolic stability data suggested that ulixertinib is moderately to highly stable under in vitro conditions using liver microsomal and hepatocytes preparations of various pre-clinical species and humans. The Caco-2 cell monolayer transport assay is well established test system for estimating drug absorption [19]. This Caco-2 cell monolayer system generated $P_{app}$ value in absorptive direction for ulixertinib was $2.67 \times 10^{-6}$ cm/sec, indicating it is a moderately permeable compound, however the $P_{app}$ value in secretive direction appeared to much higher ($8.09 \times 10^{-6}$ cm/sec), suggesting involvement of efflux transporters in the Caco-2 monolayer. Our results indicate that ulixertinib weakly inhibits the major CYPs tested and IC$_{50}$ values are greater than 20 µM (for most of CYPs tested). Ulixertinib did not show propensity to induce CYP34. So, CYP inhibition or induction is likely to represent a clinically significant risk of drug-drug interactions. Ulixertinib oral absorption in mice and rats was not limited by efflux as bioavailability in these two species was > 92 %. However in dogs the oral bioavailability was 34 % and this may be due to high unbound concentrations (fu 0.05 in dog plasma vs 0.001 and 0.003 in mice and rat plasma, respectively) in plasma and extensive metabolism in dogs thus ulixertinib had relatively high plasma clearance. In addition, higher volume of distribution of mice indicates that ulixertinib is highly distributed in mice compared to rats and dogs. Ulixertinib demonstrated high plasma clearance in dogs compared to rats and mice, which is 50, 3.0 and 7.0 % of HBF, respectively and was very much predicted by the in vitro experiment, indicating the difference in hepatic metabolism.

Conclusions

In conclusion, the preclinical data gathered in this work provided evidence that ulixertinib has excellent oral bioavailability in rodents and acceptable bioavailability in dogs, adequate metabolic stability and devoid of drug-drug interactions liability and different mechanism of action may provide differentiating features from other oncology compounds in this class. Overall, looking at the ulixertinib preclinical data presented by us and its current clinical data provide a good platform for researches to develop novel ERK1/2 inhibitors with potential benefit as a single or concomitant solid tumor therapy.
Conflict of interest: The authors have no conflict of interest

References


Preclinical assessment of ulixertinib


